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Triazole fungicide fluconazole has become the most widely used antifungal agent in the world, mainly because of its 
ability to penetrate well into body fluids and tissues. However, it has been reported to interact with many drugs and because 
of its common use, the risk of resistance to fluconazole increases. This calls for new anti-fungal drugs that would be able 
to replace it. In 2006, a new thialo benzene derivative - 2,4-dithiophenoxy-1-iodo-4-bromo benzene (C18H12S2IBr) - was 
synthesised with a carbon backbone similar to fluconazole, and, according to the early in vitro tests, much greater efficiency. 
Followed an in vitro test of its cytotoxicity, in which the new drug showed promising results as an alternative to fluconazole. 
The aim of this study was take the next step and test C18H12S2IBr toxicity in vivo. We opted for a four-week test on Wistar 
rats, in which the new antifungal agent was orally applied at doses two and a half and five times lower than those of 
fluconazole. There were no changes in daily food and water consumption, but weight gain in female rats and relative 
organ weights changed in the treated groups, pointing to sex-related differences in drug metabolism and effects. Fluconazole 
significantly increased leukocytes and lowered neutrophils whereas C18H12S2IBr did not, while other haematological 
changes in respect to the vehicle control were similar between the treated groups. Differences in cytochrome c in the liver 
and kidney suggested greater apoptotic effect of the new drug, but interpretation remains inconclusive, considering that 
other key indicators (biochemistry and histopathology) do not support greater toxicity. Considering that C18H12S2IBr is 
more active at lower concentrations and has comparable toxic effects to fluconazole in rats, this new compound shows 
some promise in the treatment of fungal infections. Future, more detailed animal studies are needed, that will include 
drug interactions and molecular toxicity pathways. If the results are promising, clinical studies should follow.
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Seventy percent of the people infected by bacteria and 
fungi develop resistance to one of the antifungal drugs (1). 
One such drug is the triazole fungicide fluconazole, and the 
risk of resistance is even greater, as fluconazole is the most 
widely used among antifungal compounds. This fungicide 
is designed to inhibit the fungal cytochrome P450 (CYP 
P450) enzyme but it can also affect the mammalian 
enzymes.
Apart from the risk of resistance to fluconazole, it has 
common side effects such as nausea, vomiting, headache, 
and toxicity issues through interactions with drugs that are 
metabolised by CYP3A4 (statins and cyclosporine). 
Therefore, it is still necessary to develop a broad-spectrum 
antifungal agent with minimal toxicity and risks for human 
health (2, 3).
In 2006, Loğoğlu et al. (4) synthesised a new thialo 
benzene derivative C18H12S2IBr with the carbon backbone 
similar to fluconazole (Figure 1) and tested its biological 
activity. 
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Figure 1  Chemical structure of A.  Fluconazole,  B. 
2,4-dithiophenoxy-1-iodo-4-bromo benzene (C18H12S2IBr)
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Its minimum inhibition concentration for Candida 
albicans was four times lower than that of fluconazole. This 
compound was also more active against Gram-positive 
(Staphylococcus aureus, Bacillus subtilis) and Gram-
negative bacteria (Yersinia enterocolitica, Escherichia coli, 
Klebsiella pneumoniae).
However, as no toxicity data on this new compound had 
been known, we tested its toxicity in vitro on L929 mouse 
fibroblast cell lines (5), using concentrations based on the 
FDA information for fluconazole (6), only to find that at 
250 µg mL-1 C18H12S2IBr was not cytotoxic and did not 
induce metabolic changes.
The next logical step was to investigate the in vivo 
toxicity of the newly synthesised compound as a potential 
alternative to flucanozole. We therefore designed this study 
to determine the toxic effects of C18H12S2IBr at subacute 
doses on the organ systems (7) of Wistar rats and compare 
them with fluconazole, considering that antifungal azoles 
have been reported to adversely affect the gastrointestinal, 
endocrinological, and liver systems (8).
MATERIALS AND METHODS
Animals and housing
The study included 50 adult Wistar male and 50 female 
rats weighing 150-200 g from the Lemali Animal 
Husbandry, Ankara, Turkey. Throughout the experiments 
we followed the National Academy of Sciences’ Guide for 
the Care and Use of Laboratory Animals (9). The rats were 
housed in polycarbonate cages under a 12:12-hour light-
and-dark cycle and controlled temperature (22±2 °C) and 
humidity (44±5 %), with free access to feed and water. 
Acclimitisation lasted 10 days. Before treatment, the rats 
were randomised to groups of 20 (10 female and 10 male), 
but we took care that the groups did not differ in body weight 
means. All rats were observed for general condition two 
times a day for the duration of the experiment.
Chemicals and treatment
2 ,4-d i th iophenoxy-1- iodo-4-bromobenzene 
(C18H12S2IBr) is one of thiohalo benzene derivatives 
synthesised by dissolving 1,2,3,5-tetrahalogene benzene in 
pyridine and adding thiophynole. This compound was 
prepared from 2,4,6-tribromo and triiodo anilines de novo, 
as described by Loğoğlu et al. (4).
Fluconazole (Fluzole® tablet, 150 mg) was purchased 
from Biofarma (Istanbul, Turkey). Fluconazole and 
C18H12S2IBr were dissolved in ethanol (absolute alcohol: 
0.145 mg kg-1 of bw) and administered by oral gavage once 
a week for four weeks. The control group was receiving no 
treatment; the vehicle group was receiving 0.145 mg kg-1 
bw of ethanol, which served as the vehicle for active 
compounds, once a week; the fluconazole group was 
receiving 19.6 mg kg-1 bw of fluconazole a week; the low-
dose C18H12S2IBr group was receiving 3.92 mg kg
-1 bw of 
C18H12S2IBr a week; and the high-dose C18H12S2IBr group 
7.84 mg kg-1 bw of C18H12S2IBr a week. The fluconazole 
dose corresponds to the 200 mg dose a 70-kg human 
receives every day during a 28-day treatment (10). The 
tested concentrations of C18H12S2IBr were two and a half 
times and five times lower than that of fluconazole, based 
on earlier in vitro efficiency findings (4), as no in vivo 
efficiency has been studied yet.
Histopathology
The animals were sacrificed by cervical dislocation 24 h 
after the final dosing. Liver, kidney, thymus, spleen, and 
lymph nodes were removed immediately and weighed to 
calculate relative organ weights (organ:body weight). All 
tissue samples were fixed in Bouin’s solution, embedded 
in paraffin, cut in 5-µm thick sections and stained with 
haemotoxylin and eosin for histopathology. The slides were 
examined under the Olympus BX51 system light 
microscope (Tokyo, Japan) at 100x and 200x magnification. 
One hundred kidney glomeruli from 20 animals from each 
group were selected to measure the minimum (x-axis) and 
maximum (y-axis) diameter in serial sections using the 
Bs200pro image analysis program (BAB, Ankara, Turkey). 
The glomerular volume was calculated as described 
elsewhere (11).
Immunohistochemistry
For immunohistochemical tests liver and kidney 
samples were fixed in 10 % formaldehyde and embedded 
in paraffin, and 5-µm sections prepared for slides. Slides 
were stained with rabbit polyclonal primary cytochrome c 
(cyt-c) antibody and biotinylated secondary goat-anti rabbit 
IgG (BA-1000, Vector Laboratories Inc.) for cyt-c as 
described by Babu et al. (12), and examined under the light 
microscope (magnification: 200x).
Endogenous peroxidase activity was quenched using 
0.3 % hydrogen peroxide in phosphate buffered saline (PBS) 
at room temperature for 30 min, as described by Koçkaya 
et al. (13). The slides were reviewed independently by three 
observers. Intensity was assessed by comparison with the 
positive and negative control sections. All slides were 
photographed with the Olympus BX51 system light 
microscope (Tokyo, Japan) and photographs analysed using 
the Bs200prop software.
Haematology and biochemistry
Twenty-four hours after the final dosing, 5 mL of blood 
was collected from the heart before cervical dislocation in 
order to make the complete blood count with a Shimadzu 
MS59 blood counting device (Kyoto, Japan).
Serum was separated from blood samples after 
centrifugation at 1800 g for 15 min and analysed for urea, 
low density lipoprotein (LDL), high density lipoprotein 
(HDL), cholesterol (Chol), aspartate aminotransferase 
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(AST), alanine aminotransferase (ALT), and lactate 
dehydrogenase (LDH) activities using commercial 
biochemical kits (Audit Diagnostics, Cork, Ireland) on a 
Shimadzu CL-770 clinical spectrophotometer (Kyoto, 
Japan) according to the manufacturer’s instructions.
Statistical analyses
For statistical analyses we used the SPSS Statistics 22 
for Windows (IBM, New York, USA). Data are expressed 
as mean±standard error (SE) and statistical significance was 
set at P≤0.05. All measured parameters were analysed 
separately for male and female rats using the two-way 
analysis of variance (ANOVA).
RESULTS AND DISCUSSION
As the control group and vehicle control group did not 
differ in any of the parameters measured, the control group 
data are not presented in this paper for the sake of space 
and readability. No clinical signs of adverse effects were 
seen in rats and none died before the end of the study. Food 
and water consumption did not vary significantly across the 
groups (Table 1). The baseline mean body weights did not 
differ significantly between the groups or sexes. The final 
mean body weights were lower in the treated groups, but 
not significantly. However, body weight gain was 
significantly lower in the treated female rats than in the 
vehicle control females as opposed to the respective male 
groups, in which no significant differences in body weight 
gain were found. This may be because of hormone (gonadal 
hormone) or fat metabolism differences between the sexes.
Table 2 points to sex differences in variations in relative 
organ weights. Female rats in the fluconazole and low-dose 
C18H12S2IBr group showed a significant increase in relative 
liver weight compared to the vehicle control, while male 
rats did not. The females in the low-dose C18H12S2IBr group 
also had significantly higher relative liver weight than the 
fluconazole group. In contrast, males did not significantly 
vary in relative liver weights.
Waxman and Holloway (14) reported that the expression 
of CYP P450 and other liver-expressed genes is sexually 
dimorphic and regulated by the levels of growth hormone 
in plasma, which is pulsatile in male animals and more 
frequent in female animals. This may explain the sex-based 
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Table 1 Food and water consumption and body weight measurements in the vehicle control and treated rats (mean±SE)
Vehicle control Fluconazole Low-dose C18H12S2IBr High-dose C18H12S2IBr
Female
Baseline body weight 112.38±6.0 124.62±5.29 124.12±4.30 121.12±5.05
Final body weight 145.37±6.11 143.12±4.12 140.37±4.18 137.5±5.50
Weight gain (%) 30.16±3.58 15.39±2.02a 13.63±1.46a 13.33±1.93a
Food consumption (g day-1) 13.85±0.84 12.05±0.48 13.23±0.38 13.86±0.42
Water consumption (mL day-1) 35.36±2.27 33.10±2.50 36.13±1.61 34.08±2.32
Male
Baseline body weight 192.12±9.86 174.87±7.35 173.87±11.29 157.5±11.79
Final body weight 236±9.57 206.37±7.69 213.5±6.57 198.25±10.53
Weight gain (%) 23.51±3.10 18.36±2.49 27.81±5.10 25.49±6.20
Food consumption (g day-1) 17.39±0.91 17.57±0.32 16.14±0.65 16.72±0.57
Water consumption (mL day-1) 37.68±3.17 35.39±1.19 36.67±2.99 37.44±3.63
aStatistically significant difference from the vehicle control group (P≤0.05)
Table 2 Relative organ weights (mean±SE) in the vehicle control and treated rats
Relative organ weight Vehicle control Fluconazole Low-dose C18H12S2IBr High-dose C18H12S2IBr
Female
Liver 3.22±0.10 3.70±0.06a 4.10±0.13a,b 3.59±0.20
Kidney 0.36±0.006 0.35±0.007 0.39±0.013 0.34±0.015c
Thymus 0.23±0.011 0.19±0.012 0.25±0.014b 0.22±0.013
Spleen 0.18±0.007 0.23±0.015a 0.28±0.006a 0.23±0.005a
Male
Liver 2.88±0.16 2.74±0.05 2.85±0.05 2.63±0.07
Kidney 0.32±0.018 0.32±0.005 0.34±0.008 0.31±0.007c
Thymus 0.11±0.008 0.12±0.009 0.12±0.009 0.12±0.012
Spleen 0.15±0.007 0.17±0.011a 0.20±0.012a 0.19±0.010a
aStatistically significant difference from the vehicle control group (P≤0.05)
bStatistically significant difference from the fluconazole group (P≤0.05)
cStatistically significant difference from the low-dose C18H12S2IBr group (P≤0.05)
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differences in drug metabolism and pharmacokinetics in 
the liver of the fluconazole and C18H12S2IBr-treated groups.
The lower relative kidney weight in the high-dose 
C18H12S2IBr group compared to vehicle control corresponds 
to the lower glomerular diameters and volume.
Relative spleen weights increased significantly in all 
treated groups compared to the vehicle control, regardless 
of sex. As, according to Sellers et al. (15), spleen and thymus 
weights tend to change naturally, we took into account 
histopathological changes in these organs and observed an 
increase in the number of megakaryocytes in the low-dose 
C18H12S2IBr group. A similar finding in mice was observed 
by Fortoul et al. (16). Our organ weight results were 
consistent with the histological findings, including 
megakaryocyte increase. Greater relative spleen weight 
may be attributed to fibrosis and increase in megakaryocyte 
count in the spleen, probably induced by fluconazole or 
C18H12S2IBr treatment.
Table 3 shows haematological variations between the 
groups. Fluconazole significantly increased leukocytes and 
lowered neutrophils whereas C18H12S2IBr did not. This may 
point to fluconazole’s greater toxicity. Fluconazole is known 
to lower the expression of various cytokine genes because 
of its lipophilic character (17). The increased glomerular 
diameter and volume in the fluconazole group seem to 
confirm the migration of neutrophils (18). As for other 
haematological parameters, all treatments had similar 
effects, and we saw no differences between fluconazole and 
C18H12S2IBr in respect to the vehicle control. It may be 
interesting to note that the pattern of variations was similar 
between the sexes: the same values rose or dropped in the 
same groups, regardless of the sex even though the doses 
received may have resulted in higher drug concentrations 
in female rats because of the lower clearance or small 
volume distribution in female tissues due to different body 
composition and organ mass.
Table 4 shows the results of the biochemical analysis 
in serum samples. Even though ALT and LDH differed 
between the fluconazole and C18H12S2IBr groups, which 
may indicate a moderate hepatic injury with leakage of liver 
enzymes, no significant changes were observed in other 
liver enzyme levels, and the new drug did not cause 
significant changes in respect to control, except for LDL.
Glomerular variations (Table 5) showed the opposite 
effects between fluconazole and C18H12S2IBr. Glomerular 
hypertrophy may be associated with hyperfiltration and 
thickening of the glomerular basement membrane after 
fluconazole treatment. In the C18H12S2IBr groups, lower 
glomerular volume may reflect inadequate filtration, kidney 
failure, and chronic kidney disease. Both changes are not 
favourable for kidney function but other parameters such 
as relative weight, histopathology, and biochemistry did 
not point to significant changes in the kidney.
Histopathology showed that C18H12S2IBr and fluconazole 
did not cause any significant changes in the liver, lymph 
nodes, and kidney tissues (Figure 2). Minor histopathological 
changes in the thymus and spleen (Figures 3, 4) were 
comparable between the fluconazole and C18H12S2IBr-
treated groups and may be explained as a mechanism for 
countering the toxic effects of fluconazole and C18H12S2IBr.
Cyt-c as a marker of liver and kidney injury in vivo has 
been investigated by several studies and can be used to 
predict drug-induced hepatotoxicity (19, 20). Figure 5 
shows more cyt-c positive hepatocytes in the C18H12S2IBr-
treated groups than in the fluconazole group. The effect of 
the new drug seems dose-dependent and suggests an 
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Figure 2 Kidney tissues stained with haematoxylin and eosin. A. Vehicle control group, B. Congestion in the low-dose C18H12S2IBr 
group (asterisk). C. Congestion in the high-dose C18H12S2IBr group (asterisk); magnification 200x
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Table 3 Haematological findings in the vehicle control and treated rats (mean±SE)





White Blood Cell (mm-3) 3.06±0.43 4.94±0.29a 4.10±0.41 4.13±0.20b
Lymphocyte % 74.48±1.60 85.67±1.38a 85.06±1.24a 81.15±2.21a
Monocyte % 7.06±0.47 4.41±0.17 5.35±0.21 6.26±0.51
Neutrophil % 10.01±1.13 5.76±0.56a 8.36±0.67 9.66±1.04
Eosinophil % 2.48±1.49 0.90±0.52 0.41±0.33 0.52±0.29
Basophil % 0.40±0.05 0.35±0.02 0.33±0.02 0.48±0.06
Erythrocytes
Red Blood Cells (mm-3) 7.42±0.23 6.56±0.29 7.02±0.08 6.35±0.30
MCV (Mean Corpuscular Volume) 47.91±0.90 54.92±0.52a 56.47±0.94a 58.16±0.24a
HCT (Haematocrit) 35.47±0.87 36.48±1.37 39.60±0.94 38.62±0.53
MCH (Mean Corpuscular Haemoglobin) 18.98±0.40 17.02±0.14a 16.45±0.12a 17.57±0.34a
MCHC (Mean Corpuscular Haemoglobin Concentration) 40.41±0.30 31.01±0.24a 30.67±1.41a 29.97±0.54a
Hb (Haemoglobin) 35.08±0.40 11.20±0.51a 11.35±0.30a 11.46±0.21a
RDW-SD (Red Cell Distribution Width-Standard 
deviation) 35.08±0.40 36.48±0.43
a 36.56±0.56a 38.01±0.81a




Thrombocyte (mm-3) 742.00±16.12 635.00±74.33 793.37±33.60 763.37±55.2
MPV (Mean Platelet Volume) 5.86±0.15 5.91±0.28 5.80±0.21 5.76±0.06
PDW (index of thrombocytes heterogeneity) 9.92±0.48 8.37±0.28 8.07±0.21 8.40±0.27
Male
Leukocytes
White Blood Cell (mm-3) 3.86±034 5.04±0.38a 3.50±0.27 3.54±0.20 
Lymphocyte % 72.87±1.37 79.61±0.96a 79.83±1.72a 77.92±1.94a
Monocyte % 6.18±0.45 6.41±0.23 6.57±0.37 6.80±0.21
Neutrophil % 13.65±0.93 9.65±0.69a 11.33±1.13 11.41±0.74
Eosinophil % 1.15±0.39 1.08±0.44 0.51±0.34 1.10±0.60
Basophil % 0.35±0.05 0.43±0.04 0.45±0.06 0.33±0.03
Erythrocytes
Red Blood Cell (mm-3) 8.60±0.18 8.37±0.17 8.23±0.13 7.90±0.19
MCV (Mean Corpuscular Volume) 46.83±0.76 55.85±0.46a 52.1±0.47a 54.9±0.74a
HCT (Haematocrit) 40.33±1.26 46.75±0.92 42.83±0.61 43.31±0.96
MCH (Mean Corpuscular Haemoglobin) 18.17±0.24 16.72±0.25a 16.58±0.28a 16.91±0.18a
MCHC (Mean Corpuscular Haemoglobin Concentration) 38.42±0.53 29.93±0.45a 31.85±0.37a 30.48±0.23a
Hb (Haemoglobin) 35.33±0.28 14.00±0.27a 13.62±0.15a 13.20±0.31a
RDW-SD (Red Cell Distribution Width-Standard 
deviation) 35.33±0.28 39.26±0.11
a 37.75±0.23a 39.28±0.28a




Thrombocyte (mm-3) 607.00±78.07 732.12±29.35 711.50±32.62 806.37±24.96
MPV (Mean Platelet Volume) 7.21±0.41 5.86±0.05 5.76±0.11 6.06±0.30
PDW (index of thrombocyte heterogeneity) 11.31±0.31 8.61±0.10 8.76±0.17 8.75±0.39
aStatistically significant difference from the vehicle control group (P≤0.05)
bStatistically significant difference from the fluconazole group (P≤0.05)
68
Table 4 Blood biochemistry in the vehicle control and treated rats (mean±SE)




AST (IU L-1) 173.31±4.49 161.75±14.91 252.57±23.96 219.67±21.17
ALT (IU L-1) 57.25±2.82 57.03±3.43 75.41±1.30b 68.18±4.11
LDL (mg dL-1) 33.52±3.94 33.28±1.10 39.98±1.71a,c 30.90±0.96
HDL (mg dL-1) 53.04±1.95 46.70±2.77 48.53±2.38 44.08±1.56
Chol (mg dL-1) 64.55±4.35 64.20±7.00 58.98±7.13 49.96±5.34
LDH (IUL-1) 2817.83±344.21 1958.50±166.12a 4858.12±325.06b 3666.50±275.17b
Urea (mg dL-1) 53.41±2.94 55.75±2.51 62.00±3.33 53.62±3.13
Male
AST (IU L-1) 236.38±20.93 217.73±9.33 226.12±12.47 250.77±17.67
ALT (IU L-1) 59.48±3.55 51.36±3.59 62.07±3.42b 57.76±5.15
LDL (mg dL-1) 30.90±0.20 38.80±1.67 42.91±2.63a,c 37.20±0.63
HDL (mg dL-1) 44.00±2.31 45.44±3.57 50.26±3.68 41.38±4.28
Chol (mg dL-1) 55.91±3.12 66.52±5.74 51.46±7.26 64.35±7.80
LDH (IU L-1) 5419.37±432.95 3206.62±402.39a 5419.00±590.95b 5155.50±526.64b
Urea (mg dL-1) 55.00±3.36 47.50±2.62 46.12±3.76 47.85±3.60
aStatistically significant difference from the vehicle control group (P≤0.05)
bStatistically significant difference from the fuconazole group (P≤0.05)
cStatistically significant difference from the high-dose C18H12S2IBr group (P≤0.05)
Figure 3 Thymus tissues stained with haematoxylin and eosin. A. Vehicle control group B. Fibrosis (arrow) in the fluconazole group, 
C. Increases in the fat cells of the connective tissue in the fluconazole group (arrow). D. Increases in the fat cells of the connective 
tissue (asterisk) in the low-dose C18H12S2IBr group. E. Enlargement of the interstitial connective tissue in the low-dose C18H12S2IBr 
group (arrow). F. Fibrosis in the high-dose C18H12S2IBr group (asterisk); magnification 100x
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Figure 4 Spleen tissues stained with haematoxylin and eosin. A. Vehicle control group; magnification 100x. B. Fibrosis 
in the fluconazole group (arrow), C. Lymphocyte depletion in the white pulp in the fluconazole group (asterisk); 
magnification 200x. D. Fibrosis (arrow) in the low-dose C18H12S2IBr group, E. Increase in megakaryocyte count in the 
low-dose C18H12S2IBr group (arrow); magnification 200x. F. Lymphocyte depletion in the white pulp in the high-dose 









Figure 5 Immunolocalisation of cyt-c in perivenular, midzonal, or periportal hepatocytes in the liver sections. Cyt-c 
positive cells (brown) A. in the vehicle control group, B. in the fluconazole group (arrow), C. In the low-dose C18H12S2IBr 
group, D. in the high-dose C18H12S2IBr group; magnification 200x
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Figure 6 Immunolocalisation of cyt-c in the kidney sections. Cyt-c positive cells (brown) A. in the proximal tubules and 
some distal tubules of the kidney cortex in the vehicle control group. B. Cortex, C. Medulla of the kidney in the fluconazole 
group. D. Cortex, E. Medulla of the kidney in the low-dose C18H12S2IBr group. Greater cyt-c-positive cell staining (brown) 
F. Cortex, G. Medulla of the kidney in the high-dose C18H12S2IBr group; magnification 200x
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Table 5 Glomerular measurements in the vehicle control and treated rats (mean±SE)
Groups Diameter of glomerulus Glomerular volume (103 µm-3)
x axis y axis
Vehicle control 65.23±0.89 81.83±1.34 218.36±8.76





aStatistically significant difference from the vehicle control group (P≤0.05)
bStatistically significant difference from the fluconazole group (P≤0.05)
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increase in the number of apoptotic cells. However, as these 
changes did not exactly match the biochemical and 
histopathological findings as the key indicators of liver 
injury, it is hard to claim that C18H12S2IBr induced liver 
toxicity.
Figure 6 compares immunolocalisation of cyt-c in the 
kidney between the vehicle control and treatment groups. 
Greater staining in the C18H12S2IBr-treated groups compared 
to fluconazole group points to greater apoptotic effect.
CONCLUSION
This study was the first to test the newly synthesised 
thialo benzene derivative C18H12S2IBr in mammals in vivo 
and to compare it to the conventional anti-fungal drug 
fluconazole. Considering that C18H12S2IBr is more active at 
lower concentrations and has comparable toxic effects to 
fluconazole in rats, this new compound shows some promise 
in the treatment of fungal infections. Future, more detailed 
animal studies are needed, that will include drug interactions 
and molecular toxicity pathways. If the results are 
promising, clinical studies should follow.
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In vivo toksičnost novoga antimikotika 2,4-ditiofenoksi-1-jodo-4-bromobenzena: proširenje in vitro istraživanja
Triazolni antifungalni lijek flukonazol danas je najrašireniji antimikotik u svijetu, mahom zato što dobro prodire u 
tjelesne tekućine i tkiva. Primijećeno je međutim da ulazi u interakciju s drugim lijekovima, a zbog česte uporabe 
sve je veći i rizik od stvaranja rezistencije na njega. Stoga se traži njegova dostojna zamjena. Godine 2006. sintetiziran 
je novi derivat tialobenzena - 2,4-ditiofenoksi-1-jodo-4-bromobenzen (C18H12S2IBr). Iako je ugljikova osnovica tog 
derivata slična onoj flukonazolu, u prvim in vitro istraživanjima pokazao se puno djelotvorniji. Uslijedilo je in vitro 
istraživanje njegove citotoksičnosti, u kojem se novi spoj pokazao obećavajućom zamjenom za flukonazol. Cilj je 
ovog istraživanja bio otići korak dalje i istražiti toksičnost C18H12S2IBr in vivo. Odlučili smo se za četverotjedno 
istraživanje na štakorima Wistar, kojima se je novi antimikotik davao na usta u dozama dva i pol i pet puta nižima 
od uobičajene doze flukonazola. U životinja nisu primijećene promjene u konzumiranju hrane i vode, ali je relativna 
težina organa u ženki bila drugačija u odnosu na kontrolnu skupinu, što upućuje na razlike između spolova u 
metabolizmu lijeka. Za razliku od C18H12S2IBr, flukonazol je prouzročio značajno povišenje razine leukocita i 
smanjenje neutrofila. Ostale hematološke promjene u odnosu na kontrolnu skupinu bile su slične u skupina koje su 
primale bilo flukonazol bilo novi lijek. Razlike u imunolokalizaciji citokroma c u jetrima i bubrezima pokazatelj 
su snažnijeg apoptotičkog učinka novoga lijeka, ali se zbog drugih ključnih pokazatelja (biokemijskih i 
histopatoloških) ne može ništa zaključiti jer oni ne odgovaraju nalazima citokroma c. S obzirom na to da C18H12S2IBr 
snažnije djeluje od flukonazola pri nižim koncentracijama, uz podjednake toksične učinke u štakora, ovaj je novi 
spoj nesumnjivo obećavajuća alternativa liječenju gljivičnih infekcija. Potrebna su daljnja, podrobnija istraživanja 
u životinja, koja će obuhvatiti interakcije spojeva i molekularne putove toksičnosti. Bude li se lijek i u tim 
istraživanjima pokazao boljom alternativom, trebalo bi provesti klinička ispitivanja u ljudi.
KLJUČNE RIJEČI: biokemija; citokrom-c; flukonazol; histopatologija; in vivo toksičnost; krv
Süloğlu AK, et al. In vivo toxicity of a new antifungal agent 2,4-dithiophenoxy-1-iodo-4-bromo benzene: a follow up on our in vitro study 
Arh Hig Rada Toksikol 2015;66:63-72
